comparemela.com
Home
Live Updates
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN...
Related Keywords
,
Hank Fuchs ,
Debra Charlesworth ,
Traci Mccarty ,
Worldwide Research ,
Exchange Commission ,
European Commission ,
Drug Administration ,
Biomarin Pharmaceutical Inc ,
Nasdaq ,
Biomarin Pharmaceutical ,
Phearless Phase ,
Data Review Board ,
Principal Investigators ,
Quarterly Report ,
Marin Pharmaceutical ,